GGHC
VRCA icon

Gilder Gagnon Howe & Co’s Verrica Pharmaceuticals VRCA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-23,412
Closed -$2.53M – 296
2019
Q1 		$2.53M Buy
23,412
+68
+0.3% +$7.84K 0.03% 193
2018
Q4 		$1.9M Buy
23,344
+6,587
+39% +$800K 0.03% 190
2018
Q3 		$2.72M Buy
16,757
+1,853
+12% +$316K 0.03% 197
2018
Q2 		$2.94M Buy
+14,904
New +$2.92M 0.03% 196

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Gilder Gagnon Howe & Co's VRCA Position: Q2 2019 in Review

Gilder Gagnon Howe & Co sold out of Verrica Pharmaceuticals (VRCA) in Q2 2019, closing a stake of 23,412 shares — an estimated $2.53M sold.

Gilder Gagnon Howe & Co first reported a position in VRCA in Q2 2018 and held it in 4 quarters. The position peaked at $2.94M in Q2 2018. 41 funds tracked by Wall St. Rank hold VRCA as of Q2 2019.

  • Gilder Gagnon Howe & Co reported no remaining Verrica Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 23,412 Verrica Pharmaceuticals shares in Q2 2019, an estimated $2.53M.
  • Gilder Gagnon Howe & Co first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Verrica Pharmaceuticals position peaked at $2.94M in Q2 2018.
  • 41 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2019.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2019, filed 13 Aug 2019.